Takeda Pharmaceutical Company Limited
Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of GPR6

Last updated:

Abstract:

Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R.sup.4, R.sup.5, R.sup.8, R.sup.10, R.sup.11, X.sup.1, X.sup.2, X.sup.3, X.sup.9, X.sup.12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.

Status:
Grant
Type:

Utility

Filling date:

26 Mar 2018

Issue date:

30 Aug 2022